Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Ludwig Rinnab"'
Autor:
Kilian M. Gust, Matthias D. Hofer, Sven R. Perner, Robert Kim, Arul M. Chinnaiyan, Sooryanarayana Varambally, Peter Moller, Ludwig Rinnab, Mark A. Rubin, Jochen Greiner, Michael Schmitt, Rainer Kuefer, Mark Ringhoffer
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 11, Iss 9, Pp 956-963 (2009)
Localized prostate cancer (CaP) can be cured using several strategies. However, the need to identify active substances in advanced tumor stages is tremendous, as the outcome in such cases is still disappointing. One approach is to deliver human tumor
Externí odkaz:
https://doaj.org/article/99aeb000597f4e1e9deb4f21c80070be
Autor:
Ludwig Rinnab, Stefanie V. Schütz, Jeannine Diesch, Evi Schmid, Rainer Küfer, Richard E. Hautmann, Klaus-Dieter Spindler, Marcus V. Cronauer
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 10, Iss 6, Pp 624-633 (2008)
The glycogen synthase kinase 3 (GSK-3) is a serine/threonine kinase widely expressed in mammalian tissues. Ini-tially identified by its ability to modulate glycogen synthesis, GSK-3 turned out to be a multifunctional enzyme, able to phosphorylate man
Externí odkaz:
https://doaj.org/article/e23f9fbd0ba147b7aa59458c5bed1a53
Autor:
Rainer Kuefer, Felicitas Genze, Waltraud Zugmaier, Richard E. Hautmann, Ludwig Rinnab, Juergen E. Gschwend, Marina Angelmeier, Aidee Estrada, Berthold Buechele
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 9, Iss 3, Pp 246-253 (2007)
Butyrates and retinoids are promising antineoplastic agents. Here we analyzed effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide (4-HPR) on prostate cancer cells as monotherapy or in combination in vitro and in vivo. Sodium butyrate and 4-
Externí odkaz:
https://doaj.org/article/0937b29f58d5409880814f61d8b12d33
Publikováno v:
Der Urologe. Ausg. ALiteraturVerwendete LiteraturWeiterführende Literatur. 60(4)
On 1 September 1958, Prof. Dr. med. Hans-Dieter Marquardt was appointed chief physician of the largest urological hospital in Germany in terms of beds at the time. As the head of the clinic from 1958 until 1983; his skills and guidance were paramount
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9d66236e655b170b5f62dfd8d75eb73d
https://pubmed.ncbi.nlm.nih.gov/31970426
https://pubmed.ncbi.nlm.nih.gov/31970426
Autor:
Mark Schrader, Marcus V. Cronauer, Henning Stemann, Friedemann Zengerling, Andres Jan Schrader, Ludwig Rinnab
Publikováno v:
The Aging Male. 15:253-257
Symptoms of the "male climacteric" are often at least in part referred to an age-dependent decline of serum androgen levels. Therefore, we evaluated the relationship of climacteric symptoms as assessed by the "Aging Males' Symptoms" (AMS) Questionnai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c354c17e2f00fd27ceea9700ffbe2d65
https://doi.org/10.3109/13685538.2012.729232
https://doi.org/10.3109/13685538.2012.729232
Publikováno v:
Der Urologe. 48:1283-1294
Extravasation of chemotherapeutic agents is a rare (1-6%) but potentially severe iatrogenic complication of systemic therapy. Depending on the cytotoxic agent, tissue damage and necrosis may occur, followed by a delay in administration of chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d42b7d3409e5f3b6d527f601f42b8c60
https://doi.org/10.1007/s00120-009-2103-4
https://doi.org/10.1007/s00120-009-2103-4
Publikováno v:
Der Urologe. 48:1295-1301
Androgen withdrawal or surgical castration remains the standard therapy for advanced prostate cancer disease. Even for castration-resistant prostate cancer the therapeutic option of docetaxel-based chemotherapy is well studied and defined. Facing dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e46fb452deb86c274daafb30d5134216
https://doi.org/10.1007/s00120-009-2111-4
https://doi.org/10.1007/s00120-009-2111-4
Publikováno v:
Der Urologe. 48:1302-1307
In cancer therapy vastly different kinds of treatment regimens, but as a rule scientifically validated and reviewed, play a central role dependent on the tumor entity. Besides the options of schoolbook medicine complementary, alternative and supporti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f349d43f6f96b0a89004821164051f3f
https://doi.org/10.1007/s00120-009-2110-5
https://doi.org/10.1007/s00120-009-2110-5
Publikováno v:
Der Urologe. 48:1308-1317
In the last 5 years the paradigms for the treatment of metastatic renal cell cancer have fundamentally changed. Until 2005 systemic therapy was limited to the immunomodulating cytokines interferon-alfa and interleukin-2, in recent years, however, tyr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b49bb8fac50144c25ea41e51788c4f78
https://doi.org/10.1007/s00120-009-2109-y
https://doi.org/10.1007/s00120-009-2109-y
Publikováno v:
Der Urologe. 48:1263-1272
Intravesical treatment with various agents is an accepted standard for treating patients with non-muscle-invasive bladder cancer; all guidelines recommend its use. Depending on the agent and the instillation schedule, a reduction in recurrence and a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a351a7e7853f804b0554ec91e0c3decf
https://doi.org/10.1007/s00120-009-2105-2
https://doi.org/10.1007/s00120-009-2105-2